Year All2024202320222021 KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH) 11-18-2022 KemPharm Reports Third Quarter 2022 Results 11-09-2022 KemPharm to Report Third Quarter 2022 Financial Results 11-01-2022 KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th 10-04-2022 KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 09-28-2022 KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference 09-01-2022 KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates 08-11-2022 KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications 08-09-2022 KemPharm to Report Second Quarter 2022 Financial Results 08-04-2022 KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference 08-02-2022
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH) 11-18-2022
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th 10-04-2022
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 09-28-2022
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications 08-09-2022